{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Su B"],"funding":["Taishan Scholars Program for Young Experts of Shangdong Province","Natural Science Foundation of Shandong Province","National Natural Science Foundation of China","Clinical Research Foundation of Shandong University"],"pagination":["3282"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11762976"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["15(1)"],"pubmed_abstract":["Previous studies have found that dyslipidemia is a risk factor for pancreatic cancer (PC), and that lipid-lowering drugs may reduce the risk of PC. However, it is not clear whether dyslipidemia causes PC. The Mendelian randomization (MR) study aimed to investigate the causal role of lipid traits in pancreatic cancer and to assess the potential impact of lipid-lowering drug targets on pancreatic cancer. Genetic variants associated with lipid traits and variants of genes encoding lipid-lowering drug targets were extracted from the Global Lipids Genetics Consortium genome-wide association study (GWAS). Summary statistics for PC were obtained from an independent GWAS datasets. Colocalization analyses were performed to validate the robustness of the results. No significant effect of lipid-lower"],"journal":["Scientific reports"],"pubmed_title":["Genetic association of lipid-lowering drug target genes with pancreatic cancer: a Mendelian randomization study."],"pmcid":["PMC11762976"],"funding_grant_id":["ZR2021LSW004","81972274","tsqn202103172","2020SDUCRCC016"],"pubmed_authors":["Wu J","Su B","Fan Z","Zhan H"],"additional_accession":[]},"is_claimable":false,"name":"Genetic association of lipid-lowering drug target genes with pancreatic cancer: a Mendelian randomization study.","description":"Previous studies have found that dyslipidemia is a risk factor for pancreatic cancer (PC), and that lipid-lowering drugs may reduce the risk of PC. However, it is not clear whether dyslipidemia causes PC. The Mendelian randomization (MR) study aimed to investigate the causal role of lipid traits in pancreatic cancer and to assess the potential impact of lipid-lowering drug targets on pancreatic cancer. Genetic variants associated with lipid traits and variants of genes encoding lipid-lowering drug targets were extracted from the Global Lipids Genetics Consortium genome-wide association study (GWAS). Summary statistics for PC were obtained from an independent GWAS datasets. Colocalization analyses were performed to validate the robustness of the results. No significant effect of lipid-lower","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jan","modification":"2026-06-01T05:54:52.048Z","creation":"2025-04-05T11:34:16.669Z"},"accession":"S-EPMC11762976","cross_references":{"pubmed":["39863728"],"doi":["10.1038/s41598-025-87490-x"]}}